Although tobacco smoking among adults has declined by 55% in the United States since 1965,
1 smoking prevalence among adults with serious mental illness remains higher now than it was in the general population in 1965.
2 Six million of the 11.4 million adults (53%) with serious mental illness smoke tobacco.
3 Relatively small trials have reported pharmacologic cessation aids—including bupropion alone or combined with nicotine replacement therapy and varenicline—increase initial abstinence rates over behavioral treatment alone for smokers with schizophrenia and schizoaffective disorder, with mean abstinence rates of 24% at the end of 8 to 12 weeks of treatment vs 5% with placebo plus behavioral therapy, suggesting behavioral treatment alone is ineffective for smoking cessation in this population.
4-11 Abstinence rates in pharmacotherapy treatment groups declined from 24% to 12% 3 months after discontinuing pharmacotherapy,
12 with some trials reporting the majority of relapses occurring within 2 weeks of stopping the medication,
8 suggesting a possible need for longer-term pharmacotherapy for prolonged tobacco abstinence in this population.